

- DeVita VT, Chu E. A history of cancer chemotherapy. *Cancer Res* 2008; 68:8643–8653.
- Lieu CH, Tan AC, Leong S, et al. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. *J Natl Cancer Inst* 2013;105:1441–1456.
- Sparreboom A, Verweij J. Advances in cancer therapeutics. *Clin Pharmacol Ther* 2009;85:113–117.
- Fujita KI, Sasaki Y. Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in 'clinical trials' to those in the 'real world'. *Drug Metab Pharmacokin* 2014;29(1):20–28.
- Lillemark J, Peterson C. Pharmacokinetic optimisation of anticancer therapy. *Clin Pharmacokinetic* 1991;21:213–231.
- Stuurman FE, Nuijen B, Beijnen JH, et al. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. *Clin Pharmacokinetic* 2013;52:399–414.
- Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. *Clin Pharmacokinetic* 2012;51:203–224.
- Cai S, Bagby TR, Forrest ML. Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies. *Ther Deliv* 2011;2:1467–1484.
- DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. *J Clin Oncol* 1998;16:2557–2567.
- Zou P, Zheng N, Yang Y, et al. Prediction of volume of distribution at steady state in humans: comparison of different approaches. *Exp Opin Drug Metab Toxicol* 2012;8:855–872.
- Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. *Clin Cancer Res* 2007;13:1663–1674.
- Pitz MW, Desai A, Grossman SA, et al. Tissue concentration of systemically administered antineoplastic agents in human brain tumors. *J Neurooncol* 2011;104:629–638.
- Mruk DD, Su L, Cheng CY. Emerging role for drug transporters at the blood-testis barrier. *Trends Pharmacol Sci* 2011;32:99–106.
- Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. *Pharm Res* 2000;17:1278–1283.
- Malingre MM, Terwogt JM, Beijnen JH, et al. Phase I and pharmacokinetic study of oral paclitaxel. *J Clin Oncol* 2000;18:2468–2475.
- Sparreboom A, Chen H, Acharya MR, et al. Effects of alpha-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. *Clin Cancer Res* 2004;10:6840–6846.
- Yamaoka K, Takakura Y. Analysis methods and recent advances in nonlinear pharmacokinetics from in vitro through in loci to in vivo. *Drug Metab Dispos* 2004;19:397–406.
- van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. *Cancer Chemother Pharmacol* 2001;47:309–318.
- Karlsson MO, Molnar V, Bergh J, et al. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression. *Clin Pharmacol Ther* 1998;63:11–25.
- Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. *AAPS J* 2011;13:111–120.
- Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. *Clin Pharmacol Ther* 2002;72:265–275.
- Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. *J Clin Oncol* 2002;20:3293–3301.
- Keams CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. *Semin Oncol* 1995;22:16–23.
- Minami H, Sasaki Y, Saijo N, et al. Indirect-response model for the time course of leukopenia with anticancer drugs. *Clin Pharmacol Ther* 1998;64:511–521.
- Latz JE, Schneck KL, Nakagawa K, et al. Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: effect of vitamin supplementation and differences between Japanese and Western patients. *Clin Cancer Res* 2009;15:346–354.
- Karlsson MO, Anehall T, Friberg LE, et al. Pharmacokinetic/pharmacodynamic modelling in oncological drug development. *Basic Clin Pharmacol Toxicol* 2005;96:206–211.
- Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. *Clin Pharmacokinetic* 2010;49:493–507.
- Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. *J Clin Oncol* 1989;7:1333–1340.
- Hainsworth JD. Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues. *Drugs* 1999;58 Suppl 3:51–56.
- Gelderblom H, Mross K, ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. *J Clin Oncol* 2002; 20:574–581.
- Woodward EJ, Twelves C. Scheduling of taxanes: a review. *Curr Clin Pharmacol* 2010;5:226–231.
- Soepenberg O, Sparreboom A, Verweij J. Clinical studies of camptothecin and derivatives. *Alkaloid Chem Biol* 2003;60:1–50.
- Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. *Nat Rev Cancer* 2005;5:447–458.
- Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. *J Clin Oncol* 1996;14:2590–2611.
- Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001. *J Natl Cancer Inst* 2002;94:1883–1888.
- Mathijssen RH, Sparreboom A. Influence of lean body weight on anticancer drug clearance. *Clin Pharmacol Ther* 2009;85:23.
- Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. *J Clin Oncol* 2007;25:4707–4713.
- Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. *Clin Pharmacokinetic* 2006;45:1077–1097.
- McLeod HL, Relling MV, Crom WR, et al. Disposition of antineoplastic agents in the very young child. *Br J Cancer* 1992;18:S23–S29.
- Hutson JR, Weitzman S, Schechter T, et al. Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. *Exp Opin Drug Metab Toxicol* 2012;8:709–722.
- Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. *J Clin Oncol* 2010;28:4790–4799.
- Lichtman SM. Pharmacology of aging and cancer: how useful are pharmacokinetic tests? *Interdiscip Top Gerontol* 2013;38:104–123.
- Relling MV, Crom WR, Pieper JA, et al. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. *Clin Pharmacol Ther* 1987;41:651–660.
- Evans WE, Rodman JH, Relling MV, et al. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia. *J Pharmacol Exp Ther* 1992;260:71–77.
- Powis G, Harris RN, Basseches PJ, et al. Effects of advanced leukemia on hepatic drug-metabolizing activity in the mouse. *Cancer Chemother Pharmacol* 1986;16:43–49.
- Charles KA, Rivory LP, Brown SL, et al. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. *Clin Cancer Res* 2006;12:7492–7497.
- Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and consequences. *Clin Pharmacol Ther* 2010;87:504–508.
- Albekairy A, Alkatheri A, Fujita S, et al. Cytochrome P450 3A4/FN011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. *Saudi J Gastroenterol* 2013;19: 89–95.
- Franke RM, Carducci MA, Rudek MA, et al. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. *J Clin Oncol* 2010;28:4562–4567.
- Rahman A, White RM. Cytotoxic anticancer agents and renal impairment study: the challenge remains. *J Clin Oncol* 2006;24:533–536.
- Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. *Cancer Res* 1985;45: 6502–6506.
- Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 1989;7:1748–1756.
- Huang SM, Temple R, Xiao S, et al. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. *Clin Pharmacol Ther* 2009;86:475–479.
- Zhang Y, Zhang L, Abraham S, et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. *Clin Pharmacol Ther* 2009;85:305–311.
- Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. *J Clin Oncol* 2008;26:570–576.
- Franke RM, Sparreboom A. Inhibition of imatinib transport by uremic toxins during renal failure. *J Clin Oncol* 2008;26:4226–4227.
- Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. *Clin Cancer Res* 1999;5:1696–1702.
- Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. *Oncology (Williston Park)* 2005;19:1057–1063.
- Hooker AC, Ten Tije AJ, Carducci MA, et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. *Clin Pharmacol Ther* 2008;84:111–118.
- Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. *Clin Pharmacokinetic* 2000;38:271–290.
- Sparreboom A, Nooter K, Loos WJ, et al. The (ir)relevance of plasma protein binding of anticancer drugs. *Neth J Med* 2001;59:196–207.
- Perdaens N, Bachaud JM, Rouzaud P, et al. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. *Eur J Clin Pharmacol* 1998;54:677–683.

63. Sparreboom A, van ZL, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. *Cancer Res* 1999;59:1454–1457.
64. Gardner ER, Burger H, van Schaik RH, et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. *Clin Pharmacol Ther* 2006;80:192–201.
65. Wu K, House L, Ramirez J, et al. Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. *Clin Cancer Res* 2013;19:6039–6043.
66. Hu S, Mathijssen RH, de Bruijn P, et al. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. *Br J Cancer* 2014;110(4):894–898.
67. Kehrer DF, Mathijssen RH, Verweij J, et al. Modulation of irinotecan metabolism by ketoconazole. *J Clin Oncol* 2002;20:3122–3129.
68. van Leeuwen RW, Brundel DH, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. *Br J Cancer* 2013;108:1071–1078.
69. Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? *Clin Pharmacol Ther* 2012;92:203–213.
70. Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. *J Clin Oncol* 2004;22:2489–2503.
71. Dy GK, Bekele L, Hanson LJ, et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. *J Clin Oncol* 2004;22:4810–4815.
72. Goey AK, Mooiman KD, Beijnen JH, et al. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. *Cancer Treat Rev* 2013;39:773–783.
73. Mathijssen RH, Verweij J, De Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. *J Natl Cancer Inst* 2002;94:1247–1249.
74. Cox MC, Low J, Lee J, et al. Influence of garlic (*Allium sativum*) on the pharmacokinetics of docetaxel. *Clin Cancer Res* 2006;12:4636–4640.
75. van Erp NP, Baker SD, Zhao M, et al. Effect of milk thistle (*Silybum marianum*) on the pharmacokinetics of irinotecan. *Clin Cancer Res* 2005;11:7800–7806.
76. Wheeler HE, Maitland ML, Dolan ME, et al. Cancer pharmacogenomics: strategies and challenges. *Nat Rev Genet* 2013;14:23–34.
77. Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. *Curr Clin Pharmacol* 2010;5:209–217.
78. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. *CA Cancer J Clin* 2009;59:42–55.
79. Evans WE, McLeod HL. Pharmacogenomics—drug disposition, drug targets, and side effects. *N Engl J Med* 2003;348:538–549.
80. Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. *Drug Resist Updat* 2003;6:71–84.
81. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. *J Natl Cancer Inst* 2006;98:1739–1742.
82. Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. *Eur J Clin Invest* 2003;33 Suppl 2:1–5.
83. Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. *Exp Opin Drug Metab Toxicol* 2005;1:429–445.
84. Sprowl JA, Mikkelsen TS, Giovinozzo H, et al. Contribution of tumoral and host solute carriers to clinical drug response. *Drug Resist Updat* 2012;15:5–20.
85. Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. *Clin Cancer Res* 2009;15:4750–4758.
86. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. *Drugs* 1998;56:1019–1038.
87. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. *N Engl J Med* 1998;338:499–505.
88. Blasdel C, Egorin MJ, Lagattuta TF, et al. Therapeutic drug monitoring in CML patients on imatinib. *Blood* 2007;110:1699–1701.
89. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. *Blood* 2008;111:4022–4028.
90. Picard S, Titier K, Etienne C, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. *Blood* 2007;109:3496–3499.
91. Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. *J Pharm Biomed Anal* 2009;49:1109–1114.
92. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. *J Natl Cancer Inst* 1995;87:573–580.
93. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. *J Clin Oncol* 1998;16:187–196.
94. Gallo JM, Laub PB, Rowinsky EK, et al. Population pharmacokinetic model for topotecan derived from phase I clinical trials. *J Clin Oncol* 2000;18:2459–2467.
95. Li J, Karlsson MO, Brahmner J, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. *J Natl Cancer Inst* 2006;98:1714–1723.
96. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. *Clin Pharmacol Ther* 2006;80:136–145.
97. Mathijssen RH, de Jong FA, Loos WJ, et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? *Oncologist* 2007;12:913–923.